Document is current
Any future updates will be listed below
-
Authors
Siebolts, Udo
Pappesch, Roberto
Bauer, Marcus
Dietmaier, Wolfgang
Ernst, Mareike
Haak, Anja
Hartmann, Nils
Ilm, Katharina
Kalbourtzis, Stavros
Krause, Thomas
Kazdal, Daniel
Schorle, Hubert
Utpatel, Kirsten
Merkelbach-Bruse, Sabine
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 26 January 2024
Revised: 29 July 2024
Accepted: 3 August 2024
First Online: 9 August 2024
Declarations
:
: Udo Siebolts and Daniel Kazdal received honoraria from Eli Lilly and Company. Thomas Krause is an employee and shareholder of Eli Lilly and Company. Other authors have no competing interests to declare. Roberto Pappesch received honoraria from ArcherDX. Udo Siebolts received financial support for participation in advisory boards from Sanofi and MSD and honoraria from AstraZeneca. Nils Hartmann received honoraria from Qiagen. Katharina Ilm received support for participation in the advisory board from Amgen GmbH. Daniel Kazdal received honoraria from Agilent, AstraZeneca, BMS, Illumina, Incyte, Pfizer, and Takeda. Hubert Schorle received a travel grant from Andronet COST Action EU framework. Sabine Merckelbach-Bruse received grants from Roche and QuIP (Quality Initiative Pathology), consulting fees from AstraZeneca, and honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, Discovery Life Science, Janssen, Menarini, Merck, Novartis, and QuIP. Other authors have no financial interests to disclose. Kirsten Utpatel participated in an advisory board with Roche. Other authors have no non-financial interests to disclose. Thomas Krause, the author of this manuscript, is an employee of Eli Lilly and Company.
